Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abemaciclib

FDA-approved product (tablet, oral), marketed as Verzenio.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Abemaciclib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • HER2 Positive Breast Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Cyclin-dependent kinase (cdk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abemaciclib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abemaciclib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Immunomonitoring of Breast Cancer Patients During Systemic Treatment

    NCT04925856 · start 2020-05-26

    Registered record
    Registry ID
    NCT04925856
    Conditions
    Breast Cancer
    Interventions
    blood sample
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2020-05-26
    Completion
    2030-05-26
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionblood sample
    PhaseNot applicable
    Registry statusRecruiting

  • Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

    NCT04305834 · start 2020-03-25

    Registered record
    Registry ID
    NCT04305834
    Conditions
    Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8
    Interventions
    Abemaciclib; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-03-25
    Completion
    2026-08-21
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8
    InterventionAbemaciclib; Questionnaire Administration
    PhasePhase 2
    Registry statusRecruiting

  • Implementing Patients´ Competence in Oral Breast Cancer Therapy

    NCT04030728 · start 2020-03

    Registered record
    Registry ID
    NCT04030728
    Conditions
    Metastatic Breast Cancer; Advanced Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-03
    Completion
    2021-12
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer; Advanced Breast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

    NCT04010357 · start 2020-01-13

    Registered record
    Registry ID
    NCT04010357
    Conditions
    Small-cell Lung Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Extrapulmonary Small Cell Carcinoma
    Interventions
    Abemaciclib,
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-13
    Completion
    2026-04-30
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall-cell Lung Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Extrapulmonary Small Cell Carcinoma
    InterventionAbemaciclib,
    PhasePhase 2
    Registry statusCompleted

  • Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

    NCT04227327 · start 2020-01-07

    Registered record
    Registry ID
    NCT04227327
    Conditions
    Advanced Breast Cancer
    Interventions
    Abemaciclib; Aromatase Inhibitors
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-01-07
    Completion
    2024-07-25
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionAbemaciclib; Aromatase Inhibitors
    PhasePhase 2
    Registry statusTerminated

  • Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

    NCT04092673 · start 2019-10-25

    Registered record
    Registry ID
    NCT04092673
    Conditions
    Solid Tumor, Adult
    Interventions
    eFT226; Sotorasib; Fulvestrant; Abemaciclib; Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2019-10-25
    Completion
    2025-03-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor, Adult
    InterventioneFT226; Sotorasib; Fulvestrant; Abemaciclib +1 more
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer

    NCT03938337 · start 2019-10-08

    Registered record
    Registry ID
    NCT03938337
    Conditions
    Head and Neck Cancer
    Interventions
    Cohort 1 Not Previously Treated; Cohort 2 Treated Previously
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-10-08
    Completion
    2020-04-03
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    InterventionCohort 1 Not Previously Treated; Cohort 2 Treated Previously
    PhasePhase 2
    Registry statusTerminated

  • Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

    NCT03997448 · start 2019-08-26

    Registered record
    Registry ID
    NCT03997448
    Conditions
    Gastroesophageal Cancer; Adenocarcinoma
    Interventions
    Pembrolizumab; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-08-26
    Completion
    2020-01-30
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Cancer; Adenocarcinoma
    InterventionPembrolizumab; Abemaciclib
    PhasePhase 2
    Registry statusTerminated

  • Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

    NCT03655444 · start 2019-05-29

    Registered record
    Registry ID
    NCT03655444
    Conditions
    Head and Neck Squamous Cell Carcinoma
    Interventions
    Abemaciclib; Nivolumab; Tumor biopsy; Peripheral blood; EORTC QLQ-30
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2019-05-29
    Completion
    2020-08-24
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Squamous Cell Carcinoma
    InterventionAbemaciclib; Nivolumab; Tumor biopsy; Peripheral blood +1 more
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

    NCT03703466 · start 2018-11-28

    Registered record
    Registry ID
    NCT03703466
    Conditions
    Metastatic Breast Cancer
    Interventions
    Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-11-28
    Completion
    2023-03-09
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionAbemaciclib
    PhasePhase 2
    Registry statusCompleted

  • Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

    NCT03425838 · start 2017-11-09

    Registered record
    Registry ID
    NCT03425838
    Conditions
    Breast Neoplasm Female
    Interventions
    CDK 4/6 inhibitor; Non-Steroidal Aromatase Inhibitor; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2017-11-09
    Completion
    2028-12
    Enrolment
    1,050

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasm Female
    InterventionCDK 4/6 inhibitor; Non-Steroidal Aromatase Inhibitor; Fulvestrant
    PhasePhase 3
    Registry statusActive not recruiting

  • CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

    NCT03227328 · start 2017-08-02

    Registered record
    Registry ID
    NCT03227328
    Conditions
    Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer
    Interventions
    concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy; chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-08-02
    Completion
    2022-07-01
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer
    Interventionconcomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy; chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
    PhasePhase 2
    Registry statusCompleted

  • Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

    NCT03220646 · start 2017-07-13

    Registered record
    Registry ID
    NCT03220646
    Conditions
    Brain Tumor
    Interventions
    abemaciclib; abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-07-13
    Completion
    2027-07
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Tumor
    Interventionabemaciclib; abemaciclib
    PhasePhase 2
    Registry statusActive not recruiting

  • Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

    NCT03155997 · start 2017-07-12

    Registered record
    Registry ID
    NCT03155997
    Conditions
    Breast Cancer
    Interventions
    Abemaciclib; Standard Adjuvant Endocrine Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2017-07-12
    Completion
    2029-05
    Enrolment
    5,637

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAbemaciclib; Standard Adjuvant Endocrine Therapy
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Abemaciclib in Recurrent Glioblastoma

    NCT02981940 · start 2017-02-09

    Registered record
    Registry ID
    NCT02981940
    Conditions
    Glioblastoma
    Interventions
    Abemaciclib; Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-02-09
    Completion
    2027-06-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma
    InterventionAbemaciclib; Surgery
    PhasePhase 2
    Registry statusActive not recruiting